Show simple item record

dc.contributor.author
Nierobisch, Nathalie
dc.contributor.author
Ludovichetti, Riccardo
dc.contributor.author
Kadali, Krishna
dc.contributor.author
Fierstra, Jorn
dc.contributor.author
Hüllner, Martin
dc.contributor.author
Michels, Lars
dc.contributor.author
Rawlings Achangwa, Ngwe
dc.contributor.author
Alcaide-Leon, Paula
dc.contributor.author
Weller, Michael
dc.contributor.author
Kulcsár, Zsolt
dc.contributor.author
Hainc, Nicolin
dc.date.accessioned
2023-09-14T12:46:35Z
dc.date.available
2023-09-14T03:26:51Z
dc.date.available
2023-09-14T11:18:18Z
dc.date.available
2023-09-14T12:46:35Z
dc.date.issued
2023-10
dc.identifier.issn
0720-048X
dc.identifier.issn
1872-7727
dc.identifier.other
10.1016/j.ejrad.2023.111076
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/631344
dc.identifier.doi
10.3929/ethz-b-000631344
dc.description.abstract
Introduction: The purpose of this retrospective study was to compare two, widely available software packages for calculation of Dynamic Susceptibility Contrast (DSC) perfusion MRI normalized relative Cerebral Blood Volume (rCBV) values to differentiate tumor progression from pseudoprogression in treated high-grade glioma patients. Material and Methods: rCBV maps processed by Siemens Syngo.via (Siemens Healthineers) and Olea Sphere (Olea Medical) software packages were co-registered to contrast-enhanced T1 (T1-CE). Regions of interest based on T1-CE were transferred to the rCBV maps. rCBV was calculated using mean values and normalized using contralateral normal- appearing white matter. The Wilcoxon test was performed to assess for significant differences, and software-specific optimal rCBV cutoff values were determined using the Youden index. Interrater reliability was evaluated for two raters using the intraclass correlation coefficient. Results: 41 patients (18 females; median age = 59 years; range 21–77 years) with 49 new or size-increasing post-treatment contrast-enhancing lesions were included (tumor progression = 40 lesions; pseudoprogression = 9 lesions). Optimal rCBV cutoffs of 1.31 (Syngo.via) and 2.40 (Olea) were significantly different, with an AUC of 0.74 and 0.78, respectively. Interrater reliability was 0.85. Discussion: We demonstrate that different clinically available MRI DSC-perfusion software packages generate significantly different rCBV cutoff values for the differentiation of tumor progression from pseudoprogression in standard-of-care treated high grade gliomas. Physicians may want to determine the unique value of their perfusion software packages on an institutional level in order to maximize diagnostic accuracy when faced with this clinical challenge. Furthermore, combined with implementation of current DSC-perfusion recommendations, multi-center comparability will be improved.
en_US
dc.format
application/pdf
en_US
dc.language.iso
en
en_US
dc.publisher
Elsevier
en_US
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Glioma
en_US
dc.subject
Astrocytoma
en_US
dc.subject
Glioblastoma
en_US
dc.subject
Perfusion weighted MRI
en_US
dc.subject
Magnetic resonance imaging
en_US
dc.title
Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma
en_US
dc.type
Journal Article
dc.rights.license
Creative Commons Attribution 4.0 International
dc.date.published
2023-09-01
ethz.journal.title
European Journal of Radiology
ethz.journal.volume
167
en_US
ethz.journal.abbreviated
Eur. J. Radiol.
ethz.pages.start
111076
en_US
ethz.size
8 p.
en_US
ethz.version.deposit
publishedVersion
en_US
ethz.identifier.wos
ethz.identifier.scopus
ethz.publication.place
Amsterdam
en_US
ethz.publication.status
published
en_US
ethz.date.deposited
2023-09-14T03:26:52Z
ethz.source
SCOPUS
ethz.eth
yes
en_US
ethz.availability
Open access
en_US
ethz.rosetta.installDate
2023-09-14T12:46:36Z
ethz.rosetta.lastUpdated
2024-02-03T03:32:42Z
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=Comparison%20of%20clinically%20available%20dynamic%20susceptibility%20contrast%20post%20processing%20software%20to%20differentiate%20progression%20from%20pseudoprogressi&rft.jtitle=European%20Journal%20of%20Radiology&rft.date=2023-10&rft.volume=167&rft.spage=111076&rft.issn=0720-048X&1872-7727&rft.au=Nierobisch,%20Nathalie&Ludovichetti,%20Riccardo&Kadali,%20Krishna&Fierstra,%20Jorn&H%C3%BCllner,%20Martin&rft.genre=article&rft_id=info:doi/10.1016/j.ejrad.2023.111076&
 Search print copy at ETH Library

Files in this item

Thumbnail

Publication type

Show simple item record